THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OF PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

1. A transmembrane delivery system comprising a reverse micelle and polar agent of interest.

2. The delivery system of claim 1, wherein said reverse micelle comprises at least one amphipathic ionic compound, and said polar agent of interest comprises at least one polar ionizable agent of interest.

3. The delivery system of claim 2, wherein said amphipathic compound is an anionic surfactant capable of forming micelles in a fluid environment.

4. The delivery system of claim 2, wherein said amphipathic compound is a cationic surfactant capable of forming micelles in a fluid environment.

5. The delivey system of claim 2, wherein said agent of interest is characterized by a partition coefficient between water and octanol at pH 7.4 of less than about 10.

6. The delivery system of claim 2, wherein said amphipathic compound is present in an amount of about 0.5 weight % to about 500 weight %.

7. The delivery system of claim 2, wherein said agent is a therapeuticaly active compound of a Class III biopharmaceutics classification and exhibits high solubility and low permeability.

8. The delivery system of claim 2, wherein the agent of interest comprises a plurality of discrete active particulates.

9. The deliver system of claim 2, wherein said amphipathic compound is an ionic surfactant or mixture of ionic surfactants selected from the group consisting of anionic surfactants, cationic surfactants and zwitterionic surfactants.

10. The delivery system of claim 9, wherein the anionic surfactants are selected from the group consisting of sodium or potassium dodecyl sulfate, sodium octadecylsulfate, sodium bis(2-ethylhexyl) sulfosuccinate (AOT), and a combination thereof.

11. The delivery system of claim 9, wherein the cationic surfactants are selected from the group consisiting of didodecyl dimethyl ammonium bromide (DDAB), cetyl-triammonium romide (CTAB), cetylpyridinium bromide (CPB), dodecyl trimethyl ammonium chloride (DOTAC), sodium perfluorononanoate (SPFN), hexadecyl trimethyl ammonium bromide (HDTMA), or a combination thereof.

12. The delivery system of claim 9, formulated into a solid tablet, matrix tablet, granules or capsule.

13. The delivery system of claim 9, further comprising one or more pharmaceutically acceptable excipients.

14. The delivery system of claim 13, wherein said one or more pharmaceutically acceptable excipients is selected from the group consisting of one or more viscosity enhancers, enteric polymers, pH-specific barrier polymers, diluents, anti-adherents, glidants, binders, solubilizers, channeling agents, wetting agents, buffering agents, flavourants, adsorbents, sweetening agents, colorants, lubricants, and a combination thereof.

15. The delivery system of claim 2, wherein the agent of interest is selected from the group consisting of one or more of an analgesic, anti-inflammatory, antimicrobial, amoebicidal, trichomonocidal agents, anti-Parkinson, anti-malarial, anticonvulsant, anti-depressants, antiarthritics, anti-fungal, antihypertensive, antipyretic, anti-parasite,

antihistamine, alpha-adrenergic agonist, alpha blocker, anaesthetic, bronchial dilator, biocide, bactericide, bacteriostat, beta adrenergic blocker, calcium channel blocker, cardiovascular drug, contraceptive, decongestants, diuretic, depressant, diagnostic, electrolyte, hypnotic, hormone, hyperglycaemic, muscle relaxant, muscle contractant, ophthalmic, parasympathomimetic, psychic energizer, sedative, sympathomimetic, tranquilizer, urinary, vaginal, viricide, vitamin, non-steroidal anti-inflammatory, angiotensin converting enzyme inhibitors, polypeptide, proteins, sleep inducers, and a combination thereof.

16. The delivery system of claim 9, wherein the system is derived from a matrix-type solid compact, made by a compression or pelletization method, or a matrix-type extrusion spheroid, made by a wet or dry extrusion method.

17. The delivery system of claim 9, wherein said system is granulated or microencapsulated to form particulates that may be compressed into solid compacts or filled into capsules.

18. The delivery system of claim 9, wherein said dosage form is selected from the group consisting of granulated, particulate, spheroidal, compact and dry blends, and wherein said system can be filled into capsules or suspended in a suitable liquid vehicle.

19. The use of the delivery system of claim 2, to deliver one or more therapeutic agents to a subject in need thereof.

20. A method of delivering a therapeutic agent to a subject in need thereof comprising,

i) formulating the delivery system of claim 2 such that the agent of interest comprises a therapeutic agent and;

ii) administering said delivery system to a subject in need thereof.

21. The method of claim 20, wherein said administering comprises oral administration.